



29 November 2019

Motif Bio plc

("Motif Bio" or the "Company")

Total Voting Rights

Motif Bio plc (AIM/Nasdaq: MTFB) announces, for the purposes of the FCA's Disclosure and Transparency Rules, that the total issued share capital of the Company consists of 485,348,166 ordinary shares of 0.01 pence each with voting rights.

The total number of voting rights in the Company is 485,348,166 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.

For further information please contact:

Motif Bio plc

Graham Lumsden (Chief Executive Officer)

ir@motifbio.com

SP Angel Corporate Finance LLP (NOMAD & BROKER)

David Hignell/Caroline Rowe (Corporate Finance)

+44 (0)20 3470 0470

Vadim Alexandre/Abigail Wayne (Sales & Broking)

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

Paul McManus/Lianne Cawthorne

+44 (0)20 7933 8780

motifbio@walbrookpr.com

MC Services AG (EUROPEAN IR)

Raimund Gabriel

+49 (0)89 210 2280

raimund.gabriel@mc-services.eu

Forward-Looking Statements

This press release contains forward-looking statements. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio's product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio's product candidates, (iii) Motif Bio's ability to successfully commercialise its product candidates, (iv) Motif Bio's ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio's commercialisation, marketing and manufacturing capabilities and strategy, (vi) Motif Bio's expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio's product candidates, (viii) Motif Bio's ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (ix) Motif Bio's estimates regarding the potential market opportunity for its product candidates, (x)

Motif Bio's ability to raise additional capital to sustain its operations and pursue its strategy and (xi) the factors discussed in the section entitled "Risk Factors" in Motif Bio's Annual Report on Form 20-F filed with the SEC on April 15, 2019, which is available on the SEC's web site, www.sec.gov. Motif Bio undertakes no obligation to update or revise any forward-looking statements.